orelabrutinib

Key facts

Mechanism of action

Tyrosine-protein kinase BTK inhibitor

Primary target: Tyrosine-protein kinase BTK

Approval history

1. Orelabrutinib Phase 3 · Zenas BioPharma · Multiple Sclerosis (MS) Primary Progressive
2. Orelabrutinib Phase 3 · Zenas BioPharma · Secondary Progressive Multiple Sclerosis
3. ZB020-03-001 Phase 3 · Zenas BioPharma · Primary Progressive Multiple Sclerosis (PPMS)
4. Orelabrutinib Phase 2 · Chinese Academy of · Follicular Lymphoma
5. Orelabrutinib Phase 2 · First People's Hospital · MALT Lymphoma
6. Orelabrutinib Phase 2 · First People's Hospital · Marginal Zone Lymphoma(MZL)
7. Orelabrutinib Phase 2 · First People's Hospital · Primary Central Nervous System Hodgkin Lymphoma
8. Orelabrutinib Phase 2 · First People's Hospital · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1. ibrutinib Antineoplastic and immunomodulating agents (L01)
2. zanubrutinib Antineoplastic and immunomodulating agents (L01)
3. acalabrutinib Antineoplastic and immunomodulating agents (L01)
4. acalabrutinib maleate Tyrosine-protein kinase BTK inhibitor
5. pirtobrutinib Antineoplastic and immunomodulating agents (L01)
6. rilzabrutinib Nervous system (NOT)

Frequently asked questions